N. Roche (Paris, France), A. Barczyk (Katowice, Poland), K.F. Chung (London, United Kingdom), M. Romagnoli (Forli, Italy)
Free triple combination of glycopyrronium, indacaterol and ICS improves lung function and dyspnoea versus free double combination of indacaterol and ICS in patients with COPD: A post-hoc analysis from the GLOW6 study
W. Vincken, J. Aumann, P. Goyal, P. Altman (Brussels, Hasselt, Belgium; Basel, Switzerland; East Hanover, United States Of America)
|   |
Analyzing the pathway to triple therapy in COPD patients: A retrospective database analysis
D. Price, R. Jones, K. Gruffydd-Jones, G. Brusselle, M. Miravitlles, M. Baldwin, R. Stewart, D. L. Keininger (Aberdeen, Plymouth, Wiltshire, Horsham, West Sussex, Cambridge, United Kingdom; Ghent, Belgium; Barcelona, Spain; Basel, Switzerland)
| |
Efficacy of aclidinium bromide in patients with stable COPD: Pooled analysis of phase III data by GOLD 2013 criteria
M. Thomas, D. Price, R. Segarra, E. Garcia Gil (Southampton, Aberdeen, United Kingdom; Barcelona, Spain)
| |
Efficacy and tolerability of aclidinium bromide/formoterol fumarate fixed-dose combination in patients with COPD: A 1-year study
B. Make, J. Donohue, W. Soong, X. Zhong, A. Leselbaum, C. Caracta (Denver, Chapel Hill, Birmingham, United States Of America; Barcelona, Spain)
| |
Effect of aclidinium/formoterol fixed-dose combinations on respiratory symptoms in COPD patients
P. Jones, A. D'Urzo, S. Rennard, E. Molins, V. Mergel, C. Caracta, A. Leselbaum (London, Omaha, Jersey City, United States Of America; Toronto, Canada; Barcelona, Spain)
| |
Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on night-time and early morning symptoms in COPD
D. Singh, K. Chapman, B. Make, M. Mocarski, C. Serra, E. Garcia Gil (Manchester, United Kingdom; Toronto, Canada; Denver, New York, United States Of America; Barcelona, Spain)
| |
Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies
S. Korn, E. Kerwin, J. F. Donohue, P. Shrestha, A. Leselbaum, A. Lei (Mainz, Germany; Medford, Chapel Hill, Jersey City, United States Of America; Barcelona, Spain)
| |
Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD
Y. Ishii, A. Takemasa, K. Chibana, R. Arai, T. Shiobara, T. Watanabe (Mibu, Japan)
| |
QVA149 improves dyspnoea and lung function versus tiotropium in symptomatic patients using LABA/ICS preceding study enrolment: The BLAZE study
A. D'Urzo, D. A. Mahler, C. Karakurum, H. Chen, R. Fogel, D. Banerji (Toronto, Canada; Hanover, East Hanover, United States Of America; Basel, Switzerland)
| |
Is therapy adherence with inhaled tiotropium in COPD related to hospitalization, pneumonia or mortality?
K. Koehorst-ter Huurne, K. Movig, P. VanderValk, J. Van der Palen, M. Brusse-Keizer (Enschede, Netherlands)
| |
Exacerbator subtypes in the tiotropium safety and performance in respimat (TIOSPIR™) trial
P. Calverley, D. Dusser, R. Wise, G. Pledger, R. Dahl, A. Mueller, J. Montero Caballero, A. Anzueto (Liverpool, United Kingdom; Sorbonne Paris Cité, Paris, France; Baltimore, Houston, San Antonio, United States Of America; Odense, Denmark; Ingelheim, Germany)
| |
Prognostic factors of mortality and cardiovascular outcomes in the tiotropium safety and performance in respimat (TIOSPIR) trial
R. Dahl, D. Dusser, R. Wise, G. Pledger, A. Anzueto, A. Mueller, A. Fowler, P. Calverley (Odense, Denmark; Sorbonne Paris Cité, Paris, France; Baltimore, Hamilton, San Antonio, United States Of America; Ingelheim, Germany; Bracknell, Liverpool, United Kingdom)
| |
Real-world prescribing patterns among newly diagnosed COPD patients receiving ICS: An analysis of UK patient dataset
D. Price, R. Jones, K. Gruffydd-Jones, G. Brusselle, M. Miravitlles, M. Baldwin, R. Stewart, D. L. Keininger (Aberbeen, Plymouth, Wiltshire, Horsham, West Sussex, Cambridge, United Kingdom; Ghent, Belgium; Barcelona, Spain; Basel, Switzerland)
| |
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
H. Watz, P. Calverley, P. Chanez, R. Dahl, M. Decramer, B. Disse, H. Finnigan, A. Kirsten, R. Rodriguez-Roisin, K. Tetzlaff, L. Towse, E. Wouters, H. Magnussen (Grosshansdorf, Ingelheim, Tübingen, Germany; Liverpool, Berkshire, United Kingdom; Marseille, France; Odense, Denmark; Leuven, Belgium; Barcelona, Spain; Maastricht, Netherlands)
| |
Is therapy adherence to inhaled corticosteroids related to hospitalization, pneumonia or mortality in COPD?
K. Koehorst-ter Huurne, K. Movig, P. VanderValk, J. Van der Palen, M. Brusse-Keizer (Enschede, Netherlands)
| |
As-needed formoterol (F) in asthma: An analysis of the East-Asian subgroup of the RELIEF study
S. G. Huang, Q. J. Cheng, M. R. Sears (Shanghai, China; Hamilton, Canada)
| |
Long-acting anticholinergics in the treatment of severe asthma with irreversible airway obstruction
O. Kharevich, I. Lapteva, E. Lapteva, G. Novskaya, I. Lantukhova, I. Dovnar, O. Burak (Minsk, Belarus)
| |
Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma
D. Halpin, E. Bateman, P. Paggiaro, E. Bleecker, M. Engel, P. Moroni-Zentgraf, H. Schmidt, H. Kerstjens (Exeter, United Kingdom; Cape Town, South Africa; Pisa, Italy; Winston-Salem, United States Of America; Ingelheim am Rhein, Biberach an der Riss, Germany; Groningen, Netherlands)
| |
Improved effects of aerosol-type fluticasone propionate/formoterol combination on residual asthmatic inflammation in distal airways of patients with moderate asthma
H. Ohbayashi (Mizunami, Japan)
| |
Experience with omalizumab in patients with moderate and severe asthma
A. L. Figueredo Cacacho, J. A. Carretero Gracia, D. Polanco Alonso, C. Viñado Mañes, C. Panadero Paz, S. García Saez, S. Gomara, E. León, A. L. Simón Robles, E. Chacón Valles, S. Bello Dronda (Saragossa, Spain)
| |